c-MET (Del Ex14)

MET · Variant type: point · HGVS: p.Del Ex14 or (Del 963-1009)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Tepotinib	95.7%	4.3%	99.75
2	Capmatinib	93.6%	6.4%	99.75
3	Gilteritinib	92.2%	7.8%	88.97
4	Deucravacitinib	80.1%	19.9%	98.99
5	Pacritinib	75.0%	25.0%	88.64
6	Tivozanib	72.5%	27.5%	92.42
7	Repotrectinib	58.9%	41.1%	84.21
8	Defactinib	55.8%	44.2%	92.68
9	Canertinib	43.2%	56.8%	96.49
10	Neratinib	38.6%	61.4%	93.18
11	Erdafitinib	38.1%	61.9%	95.71
12	Selpercatinib	33.7%	66.3%	96.72
13	Abemaciclib	29.0%	71.0%	91.48
14	Sunitinib	26.5%	73.5%	91.73
15	Entrectinib	23.8%	76.2%	93.69
16	Fedratinib	19.5%	80.5%	96.21
17	Avapritinib	17.8%	82.2%	97.73
18	Abrocitinib	16.3%	83.7%	99.50
19	Leniolisib	14.3%	85.7%	100.00
20	Erlotinib	12.8%	87.2%	99.75
21	Paxalisib	11.9%	88.1%	99.75
22	Pexidartinib	11.4%	88.6%	99.49
23	Gedatolisib	10.1%	89.9%	99.75
24	Pirtobrutinib	9.6%	90.4%	99.49
25	Upadacitinib	9.4%	90.6%	97.98

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Tepotinib	95.7%	—	—
Capmatinib	93.6%	—	—
Gilteritinib	92.2%	—	—
Deucravacitinib	80.1%	—	—
Pacritinib	75.0%	—	—
Tivozanib	72.5%	—	—
Repotrectinib	58.9%	—	—
Defactinib	55.8%	—	—
Canertinib	43.2%	—	—
Neratinib	38.6%	—	—
Erdafitinib	38.1%	—	—
Selpercatinib	33.7%	—	—
Abemaciclib	29.0%	—	—
Sunitinib	26.5%	—	—
Entrectinib	23.8%	—	—
Fedratinib	19.5%	—	—
Avapritinib	17.8%	—	—
Abrocitinib	16.3%	—	—
Leniolisib	14.3%	—	—
Erlotinib	12.8%	—	—
Paxalisib	11.9%	—	—
Pexidartinib	11.4%	—	—
Gedatolisib	10.1%	—	—
Pirtobrutinib	9.6%	—	—
Upadacitinib	9.4%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.9ms